GlassScriptPhysician profile
Todd L Clark
NPI 1407529738
$5,651.28
in general payments reported to CMS, 2019-2025
13 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $836 · 2022: $1,906 · 2023: $352 · 2024: $1,204 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,699.44 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,334.83 | 2021-2025 | Relistor, Xifaxan |
| Uswm, LLC | $1,084.91 | 2021-2023 | Lucemyra, Zimhi |
| Collegium Pharmaceutical, INC. | $906.35 | 2021-2025 | Belbuca |
| Azurity Pharmaceuticals, INC. | $156.75 | 2024-2025 | Horizant |
| Hikma Pharmaceuticals USA | $150.15 | 2021-2022 | |
| Almatica Pharma LLC | $96.37 | 2021-2023 | Gralise |
| Redhill Biopharma INC. | $88.57 | 2022 | |
| Ani Pharmaceuticals, INC. | $51.44 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $31.24 | 2021-2022 | |
| Averitas Pharma INC. | $17.44 | 2023 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $17.20 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.